^
    Back
    Association details:
    Biomarker:TMB-H + CDKN2B mutation
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASCO-GU 2023
    Title:

    Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).

    Published date:
    02/13/2023
    Excerpt:
    In TMB high pts, presence of DDR, MLL2, KDM6A, PIK3CA and TERTp alterations were each associated with improved outcomes, while presence of CDKN2B alterations was associated with inferior outcomes (Table).
    DOI:
    10.1200/JCO.2023.41.6_suppl.534